Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly dulaglutide vs glimepiride monotherapy in type 2 diabetes mellitus
KCT0000576Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jul 2012; status: recruiting.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0000576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000576.